Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3003891A

Next Previous
Drug Profile

GSK 3003891A

Alternative Names: GSK-3003891A; GSK-3003892A; GSK-3003893A; GSK-3003895A; GSK-3003896A; GSK-3003898A; GSK-3003899A; Pre F protein - GSK; RSV vaccine - GSK; RSV-PreF vaccine - GSK

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Respiratory syncytial virus vaccines; Viral fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention) in Canada (IM, Injection)
  • 05 Feb 2018 GlaxoSmithKline completes the phase II RSV F-021 trial in Respiratory syncytial virus infections (Prevention) in Belgium, Estonia, France and Germany (IM) (NCT02956837)
  • 14 Aug 2017 GlaxoSmithKline withdraws prior to enrolment a phase II trial in Respiratory syncytial virus infections (In infants, Prevention, In volunteers) in USA, Finland, Spain and United Kingdom (IM) (NCT03191383) (EudraCT2016-002733-30)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top